The efficacy of a cyclin dependent kinase 9 (CDK9) inhibitor, FIT039, on verruca vulgaris: study protocol for a randomized controlled trial
This study is the first to assess the efficacy of FIT039 and will contribute to the development of antiviral agents that can cure refractory common warts in immunocompromised patients.Trial registrationUMIN Clinical Trials,UMIN000029695. Registered on 1 November 2017.
Source: Trials - Category: Research Source Type: clinical trials
More News: Adenoviruses | Antiviral Therapy | Cancer | Cancer & Oncology | Cervical Cancer | Clinical Trials | Cold Sores | Cytomegalovirus | Drugs & Pharmacology | Epithelial Cancer | Eyes | Genital Warts | Hepatitis | Herpes | Research | Skin | Study | Warts